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Abstract
LMNA mutations are amongst the most
important causes of familial dilated cardiomy-
opathy. The most important cause of arrhyth-
mogenic right ventricular cardiomyopathy
(ARVC) is desmosomal pathology. The aim of
the study was to elucidate the role of LMNA
mutations among Finnish cardiomyopathy
patients. We screened 135 unrelated cardiomy-
opathy patients for LMNA mutations. Because
of unusual phenotype, two patients were
screened for the known Finnish ARVC-related
mutations of desmosomal genes, and their
Plakophilin-2b gene was sequenced.
Myocardial samples from two patients were
examined by immunohistochemical plakoglo-
bin staining and in one case by electron
microscopy. We found a new LMNA mutation
Phe237Ser in a family of five affected members
with a cardiomyopathy affecting primarily the
right side of the heart. The phenotype resem-
bles ARVC but does not fulfill the Task Force
Criteria. The main clinical manifestations of
the mutation were severe tricuspid insuffi-
ciency, right ventricular enlargement and fail-
ure. Three of the affected patients died of the
heart disease, and the two living patients
received heart transplants at ages 44 and 47.
Electron microscopy showed nuclear blebbing
compatible with laminopathy. Immunohisto -
chemical analysis did not suggest desmosomal
pathology. No desmosomal mutations were
found. The Phe237Ser LMNA mutation causes
a phenotype different from traditional cardio-
laminopathy. Our findings suggest that car-
diomyopathy affecting primarily the right side
of the heart is not always caused by desmoso-
mal pathology. Our observations highlight the
challenges in classifying cardiomyopathies, as
there often is significant overlap between the
traditional categories.
Introduction
Idiopathic dilated cardiomyopathy (DCM) is
characterized by left ventricular dilatation and
impaired systolic function in the absence of
hypertension, coronary artery disease, valvular
disease or other apparent cause. It is estimat-
ed to be hereditary in 25-50% of patients.1-3
Familial DCM has a diverse genetic back-
ground. So far, mutations in more than 40
autosomal genes have been found to cause
familial DCM in a typically autosomal domi-
nant inheritance pattern.3,4 Genes shown to
cause DCM can be grouped by function or cel-
lular location into nuclear envelope proteins,
such as Lamin A/C (LMNA), emerin and
nesprin, cytoskeletal proteins such as dys-
trophin, and sarcomere genes such as -
myosin heavy chain and troponin T.3 Using the
traditional Sanger sequencing a genetic cause
for familial DCM patients can be found in
about a third of the cases.5 The proportion of
patients receiving a genetic diagnosis for their
disease will likely increase with the use of next
generation sequencing techniques as suggest-
ed recently by Herman et al. reporting that
truncating titin mutations explain approxi-
mately 25% of familial DCM.6
Lamin A/C has been shown to cause 9% of
DCM leading to heart transplantation in
Finland.7 Six Lamin A/C mutations leading to
heart disease have been previously reported in
Finland.7,8 Clinical characteristics most often
associated with the Lamin A/C mutations that
cause DCM are arrhythmias, in particular atri-
al fibrillation, atrioventricular conduction
defects, and bradycardia resulting in a need of
a pacemaker, left ventricular dilatation and
eventually heart failure. The onset of clinical
manifestations of the disease is age-depend-
ent. Carriers of Lamin A/C mutations have also
been shown to be at a high risk of ventricular
arrhythmias and sudden death.9,10
Arrhythmogenic right ventricular cardiomy-
opathy (ARVC) affects primarily the right ven-
tricle, although lately biventricular and left
ventricular forms have been identified.11,12
ARVC is characterized by life-threatening
arrhythmias and the replacement of the
myocardium with fibro-fatty tissue. It has been
considered to be caused mainly by mutations
in genes encoding several desmosomal pro-
teins.13 In addition, non-desmosomal genes
such as ryanodine receptor 2 (RYR2), trans-
forming growth factor beta 3 (TGFB3), trans-
membrane protein 43 (TMEM43), and recently
LMNA, have been associated with ARVC.14-17
Surprisingly, in a population-based cohort of
over 6000 Finns, the prevalence of ARVC-relat-
ed desmosomal mutations was 1:200 suggest-
ing incomplete penetrance.18 There is signifi-
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cant overlap between the traditional clinical
subtypes of cardiomyopathy. It is not uncom-
mon for a cardiomyopathy patient to have char-
acteristics of more than one clinical subtype,
or change phenotype as the disease progress-
es. The vastly growing genetic knowledge of
cardiomyopathies also challenges the rigid
division of cardiomyopathies in to the classic
categories.1,11
In our search for new LMNA mutations in
Finnish cardiomyopathy patients we found
three new mutations and one that has been
previously reported elsewhere.19 One of the
new mutations is associated with a clinical
phenotype affecting primarily the right side of
the heart. Another new mutation is located in
the same codon as a previously described
mutation.20
Materials and Methods
We screened 133 unrelated DCM patients of
Finnish origin from the University Hospitals of
Helsinki and Kuopio recruited between 1999
and 2007 for LMNA mutations. We also includ-
ed two unrelated patients who did not fulfil all
the criteria for DCM at the time of diagnosis.
The available probands carrying Lamin A/C
mutations and their adult family members
including unrelated spouses were evaluated by
physical examination, 12-lead electrocardio-
graph, appropriate laboratory tests, transtho-
racic echocardiography (M-mode, two-dimen-
sional and Doppler) and spiroergometry. All
the available hospital records of the probands
and their family members were acquired. 
The genetic analyses concerning Lamin A/C
were performed in the Diabetes and Heart
Disease Research Unit at the University of
Eastern Finland. DNA was extracted from
peripheral blood leukocytes and amplified
using polymerase chain reaction (PCR). The
coding regions of the LMNA gene were directly
sequenced with ABIPRISM 310 or 3100 Genetic
analyzer (PE Applied Biosystems, Foster City,
CA, USA). The pathogenicity of Lamin A/C
mutations was assessed in silico using Poly
Phen-2 software.21
The genetic analyses of desmosomal pro-
teins were performed at the University of
Helsinki. All protein-coding exons and exon-
intron junctions of plakophilin-2b (PKP2b)
were amplified using PCR and sequenced with
BigDye Terminator v3.1 and ABI 3730xl DNA
Analyzer (Applied Biosystems, Carlsbad, CA,
USA). All five known Finnish ARVC-associated
mutations plakophilin-2 (PKP2) Q59L, PKP2
Q62K, PKP2 N613K, desmoplakin (DSP)
T1373A, and desmoglein-2 (DSG2)
3059_3062delAGAG were assayed using direct
sequencing or restriction enzyme assays as
described previously.18,22
Myocardial samples of the patients III:4 and
III:6 carrying the LMNA Phe237Ser mutation
were examined by immunohistochemical
analysis for the desmosomal protein plakoglo-
bin. Sections of the myocardial biopsies were
stained with plakoglobin antibody (Sigma-
Aldrich, St. Louis, MO, USA) in dilution
1:10,000 using the BenchMark immuno-stain-
er (Ventana Medical Systems Inc., Tucson, AZ,
USA). The stainings were done using the offi-
cial protocol of the BenchMark immuno-stain-
er and visualized with a peroxidase based
detection kit (UltraView Universal DAB detec-
tion kit, Ventana Medical Systems Inc., Tucson,
AZ, USA). For electron microscopy, endomy-
ocardial biopsy material was fixed in 2.5% glu-
taraldehyde in 0.1 M phosphate buffer, pH 7.4,
at room temperature for 2 h. The samples were
postfixed in 1% OsO4 for 1 h, dehydrated in
ethanol and embedded in LX112. Semithin sec-
tions were stained with toluidine blue. Thin
sections were stained with uranyl acetate and
lead citrate and examined in a Jeol 1400 elec-
tron microscope equipped with Olympus-SIS
Morada digital camera.
Parametric linkage analysis was carried out
in Pedigree 1 by utilizing the software
Merlin.23 An affected-only model was used, set-
ting the disease and marker allele frequencies
to 1/10,000, and considering family-members
with atrioventricular blocks, arrhythmias or
DCM as affected. All participants of the study
signed written informed consent. The study
protocol was approved by the Ethics
Committees of the Universities of Helsinki and
Eastern Finland, and is in compliance with the
Helsinki declaration. 
Results
We found one previously reported Lamin A/C
mutation (Arg166Pro)19 and three new muta-
tions (Phe 237Ser, c.1442 dup A, and
Glu460Asp) from the 135 cardiomyopathy
patients studied. The main clinical character-
istics associated with these mutations are
shown in Table 1. 
The Glu460Asp mutation was found in a
large family with 13 mutation carriers, the
pedigree of the family is shown in Figure 1.
The mutation was predicted to be benign using
PolyPhen-2 with a score of 0.174 (sensitivity:
0.93; specificity: 0.87). The phenotype varied
from the proband’s classical DCM with a left
ventricular ejection fraction (LVEF) of 20% at
the time of diagnosis to completely asympto-
matic. The most common findings among the
carriers of the mutation were atrioventricular
blocks necessitating pacemaker implantation.
Family-members not carrying the Glu460Asp
mutation did not display any symptoms or
signs or cardiomyopathy. Classifying family-
members with atrioventricular blocks, arrhyth-
Article
Figure 1. Pedigree of the family affected with the Glu460Asp LMNA mutation. Circles
represent women; squares men, black-filled symbols represent clinically affected; plus
sign, presence of the Glu460Asp LMNA mutation; minus sign, absence of the mutation.
Figure 2. Pedigree of the family affected
with the Arg166Pro LMNA mutation.
Circles represent women; squares men,
black-filled symbols represent clinically
affected; plus sign, presence of the
Arg166Pro LMNA mutation; minus sign,
absence of the mutation.
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mias or DCM as affected, and estimating link-
age with Glu460Asp based on a parametric
affected-only model, yielded a LOD [logarithm
(base 10) of odds] score of 2.96. The
Arg166Pro mutation (pedigree shown in
Figure 2) was also associated with a typical
cardiolaminopathy. PolyPhen-2 analysis pre-
dicted the mutation to be possibly damaging
with a score of 0.950 (sensitivity: 0.79; speci-
ficity: 0.95). In addition to DCM the proband
suffers from progressive distal sensorymotor
primary axonal polyneuropathy. The proband
carrying a Lamin A/C mutation c.1442 dup A
(pedigree shown in Figure 3) has never fully
fulfilled the criteria for DCM; however, the
course of her heart disease has been quite typ-
ical to laminopathy starting with atrial fibrilla-
tion at 41 and a non-sustained ventricular
tachycardia and an implantable cardioverter-
defibrillator implantation some 10 years later.
The fourth Lamin A/C mutation Phe237Ser
(pedigree shown in Figure 4) is associated
with an unusual cardiac phenotype affecting
primarily the right chambers of the heart. The
mutation is located in a highly conserved part
of the linker 2 domain of the protein (Figure
5). PolyPhen-2 analysis predicted the mutation
to be possibly damaging with a score of 0,691
(sensitivity: 0.86; specificity 0.92). We present
six proven carriers and two obligatory carriers
of the mutation. The mutation was not found
in any of the 186 healthy Finnish controls. 
Five family members had severe tricuspid
insufficiency, right ventricular enlargement
and right ventricular failure. Also the right
atrium was enlarged in some of the affected
patients. Moderate mitral valve regurgitation
was present in three patients. 
The proband (III:4) started showing symp-
toms of heart disease at the age of 43. He had
mild chest pain and dyspnea even at rest.
Cardiac ultrasound showed initially a dilated,
hypokinetic right ventricle, a dilated right atri-
um, a moderately dilated left ventricle, a severe
tricuspid insufficiency, and an LVEF of 40%. He
had paroxysms of atrial fibrillation soon pro-
gressing to chronic atrial fibrillation. Coronary
angiography showed no signs of coronary
artery disease. The tricuspid insufficiency was
first considered as the primary cause of right
ventricular failure, and because he was symp-
tomatic, a mechanical tricuspid valve was
installed. The main finding in the valve opera-
tion was a dilated tricuspid valve annulus.
Despite successful replacement of the tricus-
pid valve, the patient remained symptomatic.
Two years after the first signs of heart disease
echocardiography showed that the LVEF had
diminished to 35%. In follow-up the heart fail-
ure progressed. Coronary angiography showed
still no signs of coronary artery disease (CAD).
At the age of 47 he received a heart transplant.
The histological examination of the explanted
heart showed fibrotic replacement of the
Article
Figure 3. Pedigree of the family affected with the c.1442 dup A LMNA mutation. Circles
represent women; squares men, black-filled symbols represent clinically affected; plus
sign, presence of the c.1442 dup A LMNAmutation; minus sign, absence of the mutation.
Figure 4. Pedigree of the family affected with the Phe237Ser LMNA mutation. Circles
represent women; squares men, black-filled symbols represent clinically affected; plus
sign, presence of the Phe237Ser LMNA mutation; minus sign, absence of the mutation.
Figure 5. Conservation of the mutated amino acid Phe237Ser whose location is denoted
in red color. Sequences are aligned according to University of California, Santa Cruz
(UCSC) Genome Browser Vertebrate Multiz Alignment & Conservation.
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myocardium especially in the right atrium.
The proband’s brother (III:6) had atrial fib-
rillation and signs of heart failure when he
was 41 years old. Initially the echocardiogram
showed hypokinesia, a mild mitral insufficien-
cy and a significant tricuspid insufficiency. As
his brother, he also had atrial fibrillation. At an
attempted cardioversy, he went to asystole, and
consequently received a pacemaker. Less than
three years later the tricuspid insufficiency
had progressed to a severe stage. At this point
all the chambers of his heart were dilated.
Angiography showed no signs of CAD. Shortly
after his brother, he received a heart trans-
plant at the age of 44.
The proband’s cousin (III:1) presented with
a similar heart disease at 44. She had right
ventricular failure with right ventricular
dilatation and chronic atrial fibrillation. Left
ventricular diameter was normal. Electron
microscopy of the endomyocardial biopsy
showed unspecific degenerative changes in
addition to nuclear blebbing, which is com-
monly seen in Lamin A/C mutated cells, but not
in normal cells24 (Figure 6). Eighteen months
after the initial symptoms the patient received
a pacemaker because of a symptomatic brady-
cardia. At date, electrocardiogram showed vir-
tually no atrial activity. In the course of some
three years the right ventricular failure pro-
gressed. However, due to follicular lymphoma,
she was not a candidate for a heart transplant.
Two years later, she died of heart failure. Six
months prior to her death she suffered a mild
cardiogenic stroke.
According to hospital records the proband’s
mother (II:3), an obligatory mutation carrier,
had a high blood pressure before she was 30.
At 43 she received a pacemaker due to atrial
fibrillation and sick sinus syndrome. Six
months later she had a clinically diagnosed
transient ischemic attack. At 48 she suffered a
subarachnoidal haemorrhage and underwent
surgery of the ruptured aneurysm. At 53 she
was diagnosed with clinical heart failure.
Initially the most important echocardiographi-
cal finding was a significantly dilated right
side of the heart and a tricuspid insufficiency.
In addition she had a mild combined aortic
valve defect. Due to the failure of the right side
of the heart she had liver cirrhosis. She also
developed an end-stage renal failure and died
at 56. Autopsy was not performed.
The proband’s aunt (II:2) received a pace-
maker at 52 due to sick sinus syndrome and an
atrioventricular block. Echocardiography
showed initially a combined aortic valve defect,
mild mitral insufficiency and a massive tricus-
pid insufficiency. At 58 she underwent mitral
valvuloplasty and tricuspid valvuloplasty.
However surgery did not alter the outcome of
her heart disease, and 4 months after surgery
she died of heart failure.
The proband’s 24-year-old son (IV:1), 28-
Article
Figure 7. Immunohistochemical staining for the desmosomal protein plakoglobin in
heart muscle biopsies (of patients III:4 and III:6 of the family affected with the
Phe237Ser LMNA mutation). Intercalated discs show normal signal levels in a normal
control sample and in both patient samples.
Figure 6. Electron microscopy of endomyocardial biopsy (of patient III:1 of the family
affected with the Phe237Ser LMNA mutation). The shape of the cardiomyocyte nucleus
(N) in the upper panel is extensively convoluted and the nuclear membrane shows herni-
ations or blebs (b) to the cytoplasm. The lower left panel is a detail from the upper panel.
The lower right panel shows another example of nuclear blebs in a cardiomyocyte nucle-
us. The scale bar corresponds to 1 µm.
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year-old daughter (IV:2), and 22-year-old
nephew (IV:3) are all carriers of the mutation
Phe237Ser. To date, they have shown no symp-
toms of heart disease and have normal
echocardiographic findings as well as normal
findings in cardiac magnetic resonance imag-
ing. The only cardiac abnormality found in the
proband’s 22-year-old nephew is an unspecific
intraventricular conduction abnormality and a
slightly reduced performance in cardiac stress
test. The proband has a second brother (III:3)
who has no symptoms of heart disease. He
turned out to be the only family member who is
not a carrier of the new Lamin A/C mutation.
The plakoglobin staining pattern of the
Article
Table 1. The clinical manifestations associated with the LMNA mutations Glu460Asp, Arg166Pro, c. 1442 dup A and Phe237Ser. Probands
are marked in italics. 
Mutation/ F/M, DCM/ LVEF LVEDD Right Transplant ECG PM Other
mutation age HF lowest max heart 
carrier involvement
(atrium, 
ventricle, 
valves)
Glu460Asp, pedigree shown in Figure 1
III:2 F/61 n. 51 49 No No SSS, DAV III PM
III:4 F/53 n. 61 58 No No DAV I No
III:5 F/44 n. 69 52 No No Atrial and ventricular extrasystoles, DAV I No
III:10 M/61 DCM 20 59 No No FA, bradycardia, DAV III PM
III:13 M/60 No 55 58 No No FA, bradycardia, DAV III PM
III:16 M/64 No 61 56 No No FA, bradycardia, DAV III PM
III:19 F/54 No 58 56 No No FA, focal atrial tachycardia No
III:21 F/56 No 53 52 No No SSS, FA, atrial extrasystoles, bradycardia, DAV III PM
IV:1 M/32 No 62 51 No No No
IV:3 M/33 No 58 51 No No No
IV:9 F/34 No 63 55 No No Unconducted p waves in Holter No
IV:14 M/23 No 53 54 No No DAV I No
IV:16 F/17 No 70 52 No No No
Arg166Pro, pedigree shown in Figure 2
I:2 F/deceased No SVT, DAV III PM
II:2 F/71 DCM  25 54 No Yes FA, DAV III PM Progressive 
distal 
sensorymotor
primary axonal 
polyneuropathy
c.1442 dup A, pedigree shown in Figure 3
II:2 F/deceased HF Large No Ventricular extrasystoles, syncope, SSS, DAV I No
II:10 M/deceased No No SSS PM
III:6 F/60 DCM 40 62 No No FA, NSVT, bradycardia CRTD
Phe237Ser, pedigree shown in Figure 4
II:2 F/deceased HF Dilated RV, RA, TI, MI. No SSS, DAV grade nd PM
Tricuspid and 
mitral plasties 
II:3 F/deceased HF 56 43 Dilated RA, RV, 
TI, RV failure No FA, SSS PM EMB: nuclear
III:1 F/deceased HF RV dilatation and failure No FA, SSS PM blebbing
III:4 M/54 HF 30 58 Dilated RV, RA, Yes FA No
severe TI, mechanic 
tricuspid valve
III:6 M/51 HF 20 62 Severe TI Yes FA PM
IV:1 M/24 No 67 50 No No No
IV:2 F/28 No >50 43 No No No
IV:3 M/22 No 50 52 No No Slightly prolonged QRS No
M, male; F, female; DCM, dilated cardiomyopathy; HF, heart failure; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; ECG, electrocardiogram; PM, pacemaker; SSS, sick sinus syn-
drome; DAV, atrioventricular block; FA, atrial fibrillation; SVT, supraventricular tachycardia; NSVT, non-sustained ventricular tachycardia; CRTD, cardiac resynchronization therapy defibrillator; SCD, sudden cardiac
death; TI, tricuspid insufficiency; RA, right atrium; RV, right ventricle; TI, tricuspid insufficiency; MI, mitral insufficiency; EMB, endomyocardial biopsy.
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myocardial samples of the proband (III:4) and
his brother (III:6) was normal therefore sug-
gesting no underlying desmosomal pathology.
(Figure 7) In addition, the proband’s brother
(III:6) and his cousin (III:1) had no PKP2
mutations. Nor did they have any of the previ-
ously identified Finnish desmosomal muta-
tions (PKP2 Q59L, PKP2 Q62K, PKP2 N613K,
DSP T1373A and DSG2 3059_3062del
AGAG).18,22
Discussion and Conclusions
We describe one previously reported and
three new lamin A/C mutations. The
Glu460Asp mutation was found in a family
with 9 affected mutation carriers. The oldest of
the four unaffected mutation-carriers is 33
years old, which is in accordance with the age-
dependent penetrance of cardiolaminopathies.
Even if the mutation showed complete co-seg-
regation with atrioventricular blocks, arrhyth-
mias or DCM, the obtained LOD score, 2.96, is
just short of statistical significance due to the
limited number of affected meioses available
in the pedigree. In regard to the mutations
Arg166Pro and c. 1442 dup A, the families were
small and only the probands were shown to be
mutation carriers. However, as reported in
Table 1, both probands had a familial cardiomy-
opathy with a phenotype quite typical to cardi-
olaminopathy. Polyphen analysis predicted the
Arg166Pro mutation to be possibly damaging.
These findings support the idea that the muta-
tions are pathogenic. Our main finding was a
new Phe237Ser mutation of Lamin A/C gene in
patients with a severe cardiomyopathy affect-
ing primarily the right side of the heart. The
mutation resides in a conserved location of the
LMNA gene, and appears to be disease-causing
as it co-segregates with the phenotype and was
not present in healthy controls. The proband,
his brother and their female cousin all had
severe cardiac disease by their early forties,
whereas the proband’s other brother, who was
not a mutation carrier, showed no signs of car-
diac disease. The endomyocardial biopsy of the
proband’s cousin showed nuclear blebbing,
which is a typical finding in cardiolaminopa-
thy. The other three proven carriers who are
still healthy are all under 30, which is in accor-
dance with the age-dependent penetrance of
cardiolaminopathies.9,10
The Phe237Ser LMNA mutation carriers
presented with a phenotype affecting the right
side of the heart, but not fulfilling the current
Task Force criteria for ARVC.25 In addition, the
pathological changes, i.e. dilatation of the right
atrium and ventricle as well as tricuspid valve
insufficiency, were not typical for ARVC. To
further exclude ARVC, we screened the
proband’s cousin and brother for the Finnish
ARVC mutations, which were not found.
However, as a definitive exclusion of ARVC by
DNA diagnostics is not possible, and since a
reduction in immunoreactive signal levels for
plakoglobin has been introduced as a possible
diagnostic tool for ARVC,26,27 we performed
immunohistochemical analysis for the myocar-
dial samples of the proband and his brother.
The immunohistochemical staining pattern
was normal. Thus, our observations suggest
that the phenotype described here is not
caused by malfunctioning desmosomes. Our
finding differs from those of Quarta et al. who
recently reported abnormal plakoglobin stain-
ing of intercalated discs in an individual with
ARVC due to LMNA mutation Gly382Val.17
In conclusion, the Phe237Ser mutation in
Lamin A/C causes a severe phenotype of cardi-
olaminopathy leading to early death or heart
transplantation. This finding suggests that
Lamin A/C mutations should be considered
when a patient presents with a cardiomyopa-
thy affecting primarily the right side of the
heart. This is in line with the recommendation
Quarta et al. made in their recent work report-
ing LMNA mutations in ARVC patients.17 In
addition, our findings reflect the clinical chal-
lenge of dividing cardiomyopathies to their tra-
ditional categories and demonstrate the over-
lapping genetic background of cardiomyopathy
phenotypes. 
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